Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

4.2%

6 terminated/withdrawn out of 142 trials

Success Rate

92.6%

+6.1% vs industry average

Late-Stage Pipeline

11 trials in Phase 3/4

Results Transparency

3 of 75 completed trials have results

Key Signals

24 recruiting3 with results

Enrollment Performance

Analytics

N/A

49(68.1%)

Phase 3

9(12.5%)

Phase 2

6(8.3%)

Phase 1

4(5.6%)

Early Phase 1

2(2.8%)

Phase 4

2(2.8%)

72Total

N/A(49)

Phase 3(9)

Phase 2(6)

Phase 1(4)

+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (142)

Showing 20 of 142 trials

NCT04444492Phase 3Active Not Recruiting

Combination of Ranibizumab and Targeted Laser Photocoagulation

Role: lead

NCT04937361Completed

Monitoring of MDRO Dynamics and Resistance Mechanisms in a University Hospital Network

Role: collaborator

NCT07505511Early Phase 1Not Yet Recruiting

Visualization of the Effects of Guideline-directed Medical Therapy (GDMT) on Improving Adherence and Quality of Life in Heart Failure With Reduced Ejection Fraction (HFrEF)

Role: lead

NCT02684708Phase 3Completed

Second International Inter-Group Study for Classical Hodgkin Lymphoma in Children and Adolescents

Role: lead

NCT07488468Recruiting

Quality Improvement Project to Reduce Preoperative Fasting Times Before Elective Procedures

Role: lead

NCT04732910Recruiting

Modulate-CF: Cystic Fibrosis Transmembrane Regulator (CFTR) Biomarker Study to Evaluate the Rescue of Mutant CFTR in Patients With Cystic Fibrosis Treated With CFTR-modulators

Role: collaborator

NCT07422844Recruiting

Dynamic Network Response to TMS Treatment

Role: collaborator

NCT06626789Phase 1Recruiting

Brain Signal Training to Enhance Affect Down-regulation

Role: collaborator

NCT04773470Not ApplicableCompleted

Implementation of FEES in Spinal Muscle Atrophy

Role: lead

NCT06409624Active Not Recruiting

Association Between Biomarkers and Kidney Function Decline in Pulmonary Hypertension

Role: lead

NCT05374577Active Not Recruiting

Pulmonary Vascular Dysfunction as a Cause of Persistent Exertional Dyspnea After Coronavirus Disease (COVID-19)

Role: lead

NCT06027034Not ApplicableActive Not Recruiting

Effectiveness of a Digital Health Application for Psoriasis

Role: collaborator

NCT04725539Not ApplicableCompleted

Hypoxia Pre-conditioning and Mountain Sport

Role: collaborator

NCT06966739Completed

Multispectral Optoacustic Imaging in Patients With Myositis

Role: lead

NCT06365827Completed

Perioperatively Assessed Biomarker I-FABP Level for Prediction of Acute Mesenteric Ischemia and Its Correlation With Acute Kidney Injury, Followed by Extracorporeal Circulation (aMIKI)

Role: lead

NCT06406530Not ApplicableRecruiting

Topical Application of PRF Before Radiation Therapy

Role: lead

NCT06286280Not ApplicableCompleted

Removal Of CytoKines With cytoSorbenTs After Inflammatory Response Reaction During Cardiac Surgery

Role: lead

NCT06367543Completed

Guideline-recommended Basic Parameter Adherence in Neurocritical Care Patients

Role: lead

NCT05329714Recruiting

PVRI GoDeep Global Deep Phenotyping Meta-Registry for Pulmonary Hypertension